LogicBio Therapeutics
General Information | |
Business: |
We are a genome editing company focused on developing medicines to durably treat rare diseases in patients with significant unmet medical need using GeneRide, our proprietary technology platform. Our GeneRide technology is designed to precisely integrate corrective genes into a patient’s genome to provide a stable therapeutic effect. Because GeneRide is designed to have this durable therapeutic effect, we are initially targeting rare liver disorders in pediatric patients where it is critical to provide treatment early in a patient’s life before irreversible disease pathology can occur. |
Industry: | BIOLOGICAL PRODUCTS (NO DIAGNOSTIC SUBSTANCES) |
Employees: | 20 |
Founded: | 2014 |
Contact Information | |
Address | 610 Main Street, 3rd Floor, Cambridge, MA 02139, US |
Phone Number | (617) 245-0399. |
Web Address | http://www.logicbio.com |
View Prospectus: | LogicBio Therapeutics |
Financial Information | |
Market Cap | $219.38mil |
Revenues | $0 mil (last 12 months) |
Net Income | $-15.8 mil (last 12 months) |
IPO Profile | |
Symbol | LOGC |
Exchange | NASDAQ |
Shares (millions): | 7.0 |
Price range | $10.00 - $10.00 |
Est. $ Volume | $70.0 mil |
Manager / Joint Managers | Jefferies/ Barclays/ William Blair |
CO-Managers | Chardan |
Expected To Trade: | 10/19/2018 |
Status: | Priced |
Quiet Period Expiration Date: | Available only to Subscribers |
Lock-Up Period Expiration Date: | Available only to Subscribers |
SCOOP Rating | Available only to Subscribers |
Rating Change | Available only to Subscribers |